Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry J Goldstein

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Lancet (London, England)|April 13, 2005
Type 2 diabetes: principles of pathogenesis and therapyMichael Stumvoll, Barry J Goldstein, Timon W van Haeften
Endocrine Research|February 15, 2008
Pathogenesis of type 2 diabetesMichael Stumvoll, Barry J Goldstein, Timon W van Haeften
Biochemical and Biophysical Research Communications|February 10, 2004
Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDLHiroyuki Motoshima, Xiangdong Wu, Kalyankar Mahadev, et al.
Drugs|July 24, 2015
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayClaudia Filozof, Barry J Goldstein, Richard N Williams, et al.
Current Medical Research and Opinion|June 14, 2003
Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?Barry J Goldstein, Alexander R Cobitz, Linda M Hand, et al.
Antioxidants & Redox Signaling|July 7, 2005
Role of insulin-induced reactive oxygen species in the insulin signaling pathwayBarry J Goldstein, Kalyankar Mahadev, Xiangdong Wu, et al.
American Journal of Therapeutics|February 17, 2007
Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetesIntekhab Ahmed, Kevin Furlong, Jeremy Flood, et al.
Current Medical Research and Opinion|December 15, 2006
Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trialBarry J Goldstein, Julio Rosenstock, Deborah Anzalone, et al.
Diabetes|May 27, 2003
Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytesXiangdong Wu, Hiroyuki Motoshima, Kalyankar Mahadev, et al.
Cardiovascular Research|February 13, 2008
Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cellsKalyankar Mahadev, Xiangdong Wu, Sylvia Donnelly, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Lancet (London, England)|April 13, 2005
Type 2 diabetes: principles of pathogenesis and therapyMichael Stumvoll, Barry J Goldstein, Timon W van Haeften
Endocrine Research|February 15, 2008
Pathogenesis of type 2 diabetesMichael Stumvoll, Barry J Goldstein, Timon W van Haeften
Biochemical and Biophysical Research Communications|February 10, 2004
Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDLHiroyuki Motoshima, Xiangdong Wu, Kalyankar Mahadev, et al.
Drugs|July 24, 2015
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval PathwayClaudia Filozof, Barry J Goldstein, Richard N Williams, et al.
Current Medical Research and Opinion|June 14, 2003
Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?Barry J Goldstein, Alexander R Cobitz, Linda M Hand, et al.
Antioxidants & Redox Signaling|July 7, 2005
Role of insulin-induced reactive oxygen species in the insulin signaling pathwayBarry J Goldstein, Kalyankar Mahadev, Xiangdong Wu, et al.
American Journal of Therapeutics|February 17, 2007
Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetesIntekhab Ahmed, Kevin Furlong, Jeremy Flood, et al.
Current Medical Research and Opinion|December 15, 2006
Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trialBarry J Goldstein, Julio Rosenstock, Deborah Anzalone, et al.
Diabetes|May 27, 2003
Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytesXiangdong Wu, Hiroyuki Motoshima, Kalyankar Mahadev, et al.
Cardiovascular Research|February 13, 2008
Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cellsKalyankar Mahadev, Xiangdong Wu, Sylvia Donnelly, et al.
Pageof 8